JP7624220B2 - 自己抗体媒介性眼疾患の治療および診断 - Google Patents

自己抗体媒介性眼疾患の治療および診断 Download PDF

Info

Publication number
JP7624220B2
JP7624220B2 JP2021524375A JP2021524375A JP7624220B2 JP 7624220 B2 JP7624220 B2 JP 7624220B2 JP 2021524375 A JP2021524375 A JP 2021524375A JP 2021524375 A JP2021524375 A JP 2021524375A JP 7624220 B2 JP7624220 B2 JP 7624220B2
Authority
JP
Japan
Prior art keywords
ocular
disease
ophthalmic
formulation
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021524375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512946A5 (cg-RX-API-DMAC7.html
JP2022512946A (ja
Inventor
サンディープ ジェイン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2022512946A publication Critical patent/JP2022512946A/ja
Publication of JP2022512946A5 publication Critical patent/JP2022512946A5/ja
Priority to JP2025004218A priority Critical patent/JP2025061211A/ja
Application granted granted Critical
Publication of JP7624220B2 publication Critical patent/JP7624220B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021524375A 2018-11-08 2019-11-08 自己抗体媒介性眼疾患の治療および診断 Active JP7624220B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025004218A JP2025061211A (ja) 2018-11-08 2025-01-10 自己抗体媒介性眼疾患の治療および診断

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862757641P 2018-11-08 2018-11-08
US62/757,641 2018-11-08
US201962855253P 2019-05-31 2019-05-31
US62/855,253 2019-05-31
PCT/US2019/060566 WO2020097528A1 (en) 2018-11-08 2019-11-08 Treatment and diagnosis of autoantibody-mediated eye diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025004218A Division JP2025061211A (ja) 2018-11-08 2025-01-10 自己抗体媒介性眼疾患の治療および診断

Publications (3)

Publication Number Publication Date
JP2022512946A JP2022512946A (ja) 2022-02-07
JP2022512946A5 JP2022512946A5 (cg-RX-API-DMAC7.html) 2022-11-15
JP7624220B2 true JP7624220B2 (ja) 2025-01-30

Family

ID=69056109

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524375A Active JP7624220B2 (ja) 2018-11-08 2019-11-08 自己抗体媒介性眼疾患の治療および診断
JP2025004218A Pending JP2025061211A (ja) 2018-11-08 2025-01-10 自己抗体媒介性眼疾患の治療および診断

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025004218A Pending JP2025061211A (ja) 2018-11-08 2025-01-10 自己抗体媒介性眼疾患の治療および診断

Country Status (10)

Country Link
US (1) US20220062337A1 (cg-RX-API-DMAC7.html)
EP (1) EP3877406A1 (cg-RX-API-DMAC7.html)
JP (2) JP7624220B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210093274A (cg-RX-API-DMAC7.html)
CN (1) CN113631570B (cg-RX-API-DMAC7.html)
AU (1) AU2019377552B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008548A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118367A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005352A (cg-RX-API-DMAC7.html)
WO (1) WO2020097528A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100002306A1 (it) * 2021-02-03 2022-08-03 Univ Degli Studi Roma La Sapienza Procedimento e kit per la diagnosi in vitro della sindrome da anticorpi anti-fosfolipidi
US11951123B2 (en) * 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
WO2023201283A2 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Methods of producing plasma or serum and uses thereof
WO2024077068A1 (en) * 2022-10-06 2024-04-11 Oklahoma Medical Research Foundation Anti-vimentin antibodies are associated with higher severity of sjögren's syndrome
WO2024136368A1 (ko) * 2022-12-21 2024-06-27 건국대학교 산학협력단 α-2,6-시알산화 면역글로불린의 안구 건조증 또는 염증성 안과 질환의 예방 또는 치료 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504268A (ja) 2003-09-05 2007-03-01 タレクリス・バイオセラピユーテイクス・インコーポレーテツド ヘルペス感染症を処置するための方法および組成物
JP2015536317A (ja) 2012-10-17 2015-12-21 リバプール・スクール・オブ・トロピカル・メディスン 免疫調節タンパク質

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107906B1 (en) * 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504268A (ja) 2003-09-05 2007-03-01 タレクリス・バイオセラピユーテイクス・インコーポレーテツド ヘルペス感染症を処置するための方法および組成物
JP2015536317A (ja) 2012-10-17 2015-12-21 リバプール・スクール・オブ・トロピカル・メディスン 免疫調節タンパク質

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Frontiers in Immunology,2017年,Vol. 8, Article 603

Also Published As

Publication number Publication date
WO2020097528A1 (en) 2020-05-14
US20220062337A1 (en) 2022-03-03
MX2021005352A (es) 2021-09-14
KR20210093274A (ko) 2021-07-27
AU2019377552A1 (en) 2021-05-27
CA3118367A1 (en) 2020-05-14
AU2019377552B2 (en) 2026-07-23
BR112021008548A2 (pt) 2021-08-03
EP3877406A1 (en) 2021-09-15
JP2022512946A (ja) 2022-02-07
CN113631570B (zh) 2026-06-02
JP2025061211A (ja) 2025-04-10
CN113631570A (zh) 2021-11-09

Similar Documents

Publication Publication Date Title
JP2025061211A (ja) 自己抗体媒介性眼疾患の治療および診断
Hassanpour et al. Peripheral ulcerative keratitis: a review
US9877645B2 (en) Inflammatory eye disorders
Phadatare et al. A comprehensive review on dry eye disease: diagnosis, medical management, recent developments, and future challenges
Magli et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis
Al-Saedi et al. Dry eye disease: present challenges in the management and future trends
Airody et al. Non-infectious uveitis: optimising the therapeutic response
US20210322457A1 (en) Treatment and diagnosis of ocular surface disorders
CN1964719B (zh) 依碳酸氯替泼诺用于制备治疗干眼症的药物的用途
KR20170048426A (ko) 시각 장애를 치료하기 위한 조성물 및 방법
HK1247120A1 (zh) 用於治疗眼部炎性病症含有整联蛋白α4拮抗剂的药物组合物
JP2022512946A5 (cg-RX-API-DMAC7.html)
JP6544806B2 (ja) 眼疾患の治療および診断
Long et al. Clinical features and in vivo confocal microscopy assessment in 12 patients with ocular cicatricial pemphigoid
Pham et al. Use of infliximab in the treatment of peripheral ulcerative keratitis in Crohn disease
Heiligenhaus et al. Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study
WO2020157570A1 (en) Hyaluronic acid for relief of idiopathic ocular pain
Gong et al. Recurrent corneal melting in the paraneoplastic pemphigus associated with Castleman’s disease
RU2845362C2 (ru) Лечение и диагностика опосредованных аутоантителами глазных заболеваний
JP2018508514A (ja) ドライアイ疾患を治療及び/又は予防するための短い合成ペプチドの使用
EP4640702A1 (en) Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases
Muna et al. Ocular cicatricial pemphigoid
GÜNDÜZ Fungal Infections and Management in Geriatric Population
Saw The role of inflammation and fibroblasts in conjunctival scarring in ocular mucous membrane pemphigoid
Swan et al. Diagnosis and management of cicatricial conjunctivitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250110

R150 Certificate of patent or registration of utility model

Ref document number: 7624220

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150